Hypothermic versus Normothermic Temperature Control after Cardiac Arrest

Holgersson, Johan; Meyer, Martin Abild Stengaard; Dankiewicz, Josef; Lilja, Gisela; Ullén, Susann; Hassager, Christian; Cronberg, Tobiás; Wise, Matt P.; Bělohlávek, Jan; Hovdenes, Jan; Pelosi, Paolo; Erlinge, David; Schrag, Claudia; Smid, Ondrej; Brunetti, Iole; Rylander, Christian; Young, Paul J.; Saxena, Manoj; Åneman, Anders; Cariou, Alain; Callaway, Clifton; Eastwood, Glenn M.; Haenggi, Matthias; Joannidis, Michael; Keeble, Thomas R.; Kirkegaard, Hans; Leithner, Christoph; Levin, Helena; Nichol, Alistair D.; Morgan, Matt P. G.; Nordberg, Per; Oddo, Mauro; Storm, Christian; Taccone, Fabio Silvio; Thomas, Matthew; Bro-Jeppesen, John; Horn, Janneke; Kjaergaard, Jesper; Kuiper, Michael; Pellis, Tommaso; Stammet, Pascal; Wanscher, Michael Jaeger; Friberg, Hans; Nielsen, Niklas; Jakobsen, Janus Christian

Published in:
NEJM Evidence

DOI:
10.1056/evidoa2200137

Publication date:
2022

Document version:
Final published version

Citation for published version (APA):

Go to publication entry in University of Southern Denmark's Research Portal

Terms of use
This work is brought to you by the University of Southern Denmark.
Unless otherwise specified it has been shared according to the terms for self-archiving.
If no other license is stated, these terms apply:

• You may download this work for personal use only.
• You may not further distribute the material or use it for any profit-making activity or commercial gain
• You may freely distribute the URL identifying this open access version
Hypothermic versus Normothermic Temperature Control after Cardiac Arrest

Johan Holgersson, M.D.,* Martin Abild Stengaard Meyer, M.D.,* Josef Dankiewicz, M.D., Ph.D.,* Susann Ullén, Ph.D.,* Christian Hassager, M.D., D.M.Sc.,* Tobias Cronberg, M.D., Ph.D.,* Matt P. Wise, M.B.B.Ch., D.Phil., Jan Belohlávek, M.D., Ph.D.,† Jan Hovdenes, M.D., Ph.D.,§ Paolo Pelosi, M.D., Ph.D.,¶ David Erlinge, M.D., Ph.D., Claudia Schrag, M.D.,¶ Ondrej Smid, M.D., Iole Brunetti, M.D., Christian Rylander, M.D., Ph.D., Paul J. Young, M.D., Ph.D., Manoj Saxena, M.B.B.Ch., Ph.D., Christian Hassager, M.D., D.M.Sc., Tobias Cronberg, M.D., Ph.D., Claudia Schrag, M.D.,* Manoj Saxena, M.B.B.Ch., Ph.D., Anders Åneman, M.D., Ph.D., Alain Cariou, M.D., Ph.D., Claudio Callaway, M.D., Ph.D., Glenn M. Eastwood, R.N., Ph.D., Matthias Haenggi, M.D., Michael Joannidis, M.D., Thomas R. Keeble, M.B.B.S., M.D., Hans Kirkegaard, M.D., D.M.Sc., Christoph Leithner, M.D., Helena Levin, M.Sc., Alistair D. Nichol, M.B., Ph.D., Matt P. G. Morgan, M.B.B.Ch., Ph.D., Per Nordberg, M.D., Ph.D., Mauro Oddo, M.D., Christian Storm, M.D., Ph.D., Fabio Silvio Taccone, M.D., Ph.D., Matthew Thomas, M.B.B.Ch., John Bro-Jeppesen, M.D., D.M.Sc., Janneke Horn, M.D., Ph.D., Jesper Kjaergaard, M.D., D.M.Sc., Michael Kuiper, M.D., Ph.D., Tommaso Pellis, M.D., Pascal Stammet, M.D., Ph.D., Michael Jaeger Wanscher, M.D., Ph.D., Hans Friberg, M.D., Ph.D., Niklas Nielsen, M.D., Ph.D., and Janus Christian Jakobsen, M.D., Ph.D.

Abstract

BACKGROUND The evidence for temperature control for comatose survivors of cardiac arrest is inconclusive. Controversy exists as to whether the effects of hypothermia differ per the circumstances of the cardiac arrest or patient characteristics.

METHODS An individual patient data meta-analysis of the Targeted Temperature Management at 33°C versus 36°C after Cardiac Arrest (TTM) and Hypothermia versus Normothermia after Out-of-Hospital Cardiac Arrest (TTM2) trials was conducted. The intervention was hypothermia at 33°C and the comparator was normothermia. The primary outcome was all-cause mortality at 6 months. Secondary outcomes included poor functional outcome (modified Rankin scale score of 4 to 6) at 6 months. Predefined subgroups based on the design variables in the original trials were tested for interaction with the intervention as follows: age (older or younger than the median), sex (female or male), initial cardiac rhythm (shockable or nonshockable), time to return of spontaneous circulation (above or below the median), and circulatory shock on admission (presence or absence).

RESULTS The primary analyses included 2800 patients, with 1403 assigned to hypothermia and 1397 to normothermia. Death occurred for 691 of 1398 participants (49.4%) in the hypothermia group and 666 of 1391 participants (47.9%) in the normothermia group (relative risk with hypothermia, 1.03; 95% confidence interval [CI], 0.96 to 1.11; P = 0.41). A poor functional outcome occurred for 733 of 1350 participants (54.3%) in the hypothermia group.

*Drs. Holgersson and Meyer are co-first authors.
†Drs. Nielsen and Jakobsen are co-last authors.

The author affiliations are listed at the end of the article.

Dr. Nielsen can be contacted at niklas.nielsen@med.lu.se or at Departments of Clinical Sciences, and Anesthesiology and Intensive Care, Helsingborg Hospital, Lund University, S. Vallgatan 5, 251 87 Helsingborg, Sweden.
and 718 of 1330 participants (54.0%) in the normothermia group (relative risk with hypothermia, 1.01; 95% CI, 0.94 to 1.08; P=0.88). Outcomes were consistent in the predefined subgroups.

CONCLUSIONS Hypothermia at 33°C did not decrease 6-month mortality compared with normothermia after out-of-hospital cardiac arrest. (Funded by Vetenskapsrådet; ClinicalTrials.gov numbers NCT02908308 and NCT01020916.)

Introduction

Temperature control has been one of the cornerstones in the treatment and prevention of brain injury and associated death or disability for comatose resuscitated patients with out-of-hospital cardiac arrest.1,2 Hypothermic temperature control was included in guidelines based on two trials published in 2002 that included a total of 359 patients with out-of-hospital cardiac arrest with a presumed cardiac cause of arrest and an initial shockable cardiac rhythm.1,3,4 Results of these trials suggested that temperature control at 33°C had a beneficial effect on neurologic function, but both trials had limited power to assess plausible intervention effects and were at high risk of bias.5 Since the introduction of hypothermia after cardiac arrest in guidelines, three major trials have been conducted comparing hypothermia to normothermia.6-8

The HYPERION trial was published in 2019. HYPERION randomly assigned 584 patients with both in- and out-of-hospital cardiac arrest with an initial nonshockable rhythm exclusively.7 In line with the original investigations that led to the widespread introduction of hypothermic temperature control after out-of-hospital cardiac arrest, the trial investigators found a higher percentage of participants surviving with a favorable neurologic outcome compared with targeted normothermia, but there was no significant difference in mortality.7

In contrast, the Target Temperature Management at 33°C versus 36°C after Out-Of-Hospital Cardiac Arrest (TTM) trial compared the hypothermic target temperature of 33°C with 36°C. The investigators found no benefit of temperature control at 33°C compared with 36°C.9 The clinical applicability of these findings was challenged by perceived limitations, including that both trial groups received mandatory temperature control. To address this, the Hypothermia versus Normothermia after Out-Of-Hospital Cardiac Arrest (TTM2) trial compared a target temperature of 33°C with normothermia in participants with out-of-hospital cardiac arrest.8 Normothermia was defined as a temperature of 37.8°C or lower, and a temperature above this triggered the use of a temperature management device to target a temperature of 37.5°C. The TTM2 trial investigators concluded that there was no benefit on survival or neurologic outcome of 33°C compared with normothermia.

Building on the expanded evidence base,9 recently updated guidelines on temperature control after cardiac arrest no longer specifically recommend use of temperature control at 32 to 36°C for comatose resuscitated patients with out-of-hospital cardiac arrest; as an alternative treatment option, they introduce a strategy of normothermia and fever prevention.10 Despite a lack of evidence of benefit from hypothermia in the meta-analysis that informed the guidelines, hypothermic temperature control was retained as a treatment option. This decision acknowledged a hypothetical beneficial effect of hypothermia in certain circumstances,10 including in patients with nonshockable initial rhythm and for those with more severe hypoxic-ischemic injury.11-13

For both the TTM and TTM2 trials, the intervention was hypothermia at 33°C; furthermore, the comparators in both trials were within the normothermic range.6,9,14,15 The trials had similar methodology with protocols emphasizing strict neuroprognostication, withdrawal of life support, and a structured face-to-face follow-up.6,8 In this report we provide an individual patient data meta-analysis of the results of the TTM and TTM2 trials by combining the two intervention groups and the two comparator groups, thereby providing greater statistical power than the individual trials. Accordingly, we evaluated the overall evidence on the effect of hypothermia after out-of-hospital cardiac arrest and investigated whether certain subgroups might benefit from hypothermic temperature control.

Methods

The design and results of the TTM and TTM2 trials were published previously.16,17 The populations in both trials were adults who experienced an out-of-hospital cardiac arrest of a presumed cardiac or unknown cause with return of spontaneous circulation. Patients were eligible for enrollment if they met all inclusion criteria and no exclusion criteria (Table S1 in the Supplementary Appendix). The intervention was 33°C for both the TTM and TTM2 trials. Similarly, a normothermic strategy was a applied as the comparator in...
both trials: a target temperature of 36°C was used as the control intervention in the TTM trial, and the control intervention was maintenance of normothermia with treatment of fever (≥37.8°C) in the TTM2 trial.6,9

STUDY DESIGN
This individual patient data meta-analysis was conducted in accordance with a protocol that was registered before analysis, and any deviations are reported.18 We included individual patient data from the TTM and TTM2 trials. Separate ethics approval for this study was not required, as each trial was approved by ethics committees and authorities in each participating country.

OUTCOMES
The primary outcome was all-cause mortality. Secondary outcomes were poor functional outcome (modified Rankin scale score of 4 to 6), pneumonia, sepsis, and severe bleeding. Exploratory outcomes were time to death (survival data), functional outcome (modified Rankin scale score, ordinal outcome), and observed functional outcome stratified by a low, intermediate, or high admission MIRACLE2 score (defined as a score of 0 to 2, 3 to 4, or ≥5, respectively, where higher scores denote higher risk of poor neurologic outcome).19 Our assessment time point for mortality and functional outcome was at 6 months after randomization for each participant. The secondary outcomes of pneumonia, sepsis, and serious bleeding were assessed until day 7 of the indexed intensive care unit admission for each participant.

RISKS OF BIAS
For each outcome of interest, an external collaborator at McMaster University assessed the likelihood that confounding, selection, measurement, and reporting biases have affected the trials’ estimates, following the Cochrane Risk-of-Bias Tool.20

STATISTICAL ANALYSES
Analyses included the modified intention-to-treat population from the TTM trial6 and the intention-to-treat population from the TTM2 trial.17 We assessed whether the thresholds for statistical significance and clinical significance were crossed, including Bayes factor calculations.21 The Bayes factor indicates whether the obtained results are most likely under the null hypothesis or the alternative hypothesis (anticipated intervention effect). A value greater than 1 indicates support for the null hypothesis, whereas a value less than 1 indicates support for the alternative hypothesis.21 Assessment of clinical significance was based on the anticipated intervention effects used in the sample size/power estimations in the TTM2 trial, set at 55% risk of mortality in the normothermia group and an absolute risk reduction of 7.5% by hypothermia corresponding to a relative risk reduction of 13.6% (the same estimated risk and risk reduction was applied for poor functional outcome).17,23 Our primary conclusion was based on one primary outcome, and all tests of statistical significance (including subgroup analyses) were two sided with a type I error risk of 5%.25 Because the secondary outcome results and subgroup analyses were only hypothesis generating, we made no corrections for multiplicity. Regression analyses for the primary and secondary outcomes were adjusted for site. We systematically assessed whether the underlying statistical assumptions behind the statistical analyses were violated.24

We performed analyses of an interaction between the intervention and the subgroups first presenting cardiac rhythm (nonshockable compared with shockable initial rhythm), time to return of spontaneous circulation (at or above the median compared with below the median), presence of circulatory shock on admission (circulatory shock not present on admission compared with circulatory shock present on admission), sex (male compared with female), and age (at or above the median compared with below the median). As a post hoc analysis, we also performed a test of interaction for observed functional outcome stratified by a low, intermediate, or high admission MIRACLE2 score, which has previously been validated as a means for assessment of severity and risk for a poor outcome after out-of-hospital cardiac arrest. We used the same categorization as the original MIRACLE2 publication (low, intermediate, and high risk groups defined as a score of 0 to 2, 3 to 4, or ≥5, respectively).19 For a description of this analysis, see the analysis of severity discussion in the Supplementary Appendix. Post hoc, we also added the subgroups, time to advanced life support (at or above the median compared with below the median), presence or absence of bystander resuscitation, and whether the cardiac arrest was witnessed.

Dichotomous outcomes were analyzed by mixed-effects generalized linear models using a logit link function with site as random intercept using an unstructured covariance matrix (an exchangeable covariance matrix was planned but not feasible). Sites that participated in both the TTM and TTM2 trials were assigned separate site identities. An interaction term was added to the mixed-effects model when comparing subgroups. Results are presented as proportions of participants in each group with the event as well as risk ratios with 95% confidence intervals (CIs).

NEJM EVIDENCE
Risk ratios were calculated based on odds ratios using the G-computation. Modified Rankin scale score (ordinal) was analyzed using a Mann-Whitney U test. Missing data were handled according to Jakobsen et al. Because missingness was rare, complete case analyses were performed for all predefined analyses.

To control the risk of random errors, we performed trial sequential analysis on all primary and secondary outcomes. Required information sizes were calculated for the meta-analyses (i.e., the number of participants needed in a meta-analysis to detect or reject a certain intervention effect) and relevant trial sequential monitoring boundaries (boundary for benefit, harm, and futility). For dichotomous outcomes, we estimated the required information sizes based on the observed proportion of participants with an outcome in the control group, an alpha of 5%, and a beta of 10%. We estimated the lowest effect estimate that could be rejected using trial sequential analysis.

**STATISTICAL ANALYSIS**

Data on all outcomes were analyzed in duplicate and independently (by S.U. and J.D.). Two independent statistical reports were sent to the chief principal investigator and were shared with the steering and author groups. Discrepancies between the two primary statistical reports were identified and the steering group decided which was the most correct result. A final statistical report was prepared. Statistical reports are available in the Supplementary Appendix.

---

**Results**

**PARTICIPANTS AND INTERVENTION**

From November 2010 to January 2013 for TTM and from November 2017 to January 2020 for TTM2, the two trials randomly assigned 2850 patients with out-of-hospital cardiac arrest at 65 hospitals in Australia, Austria, Belgium, the Czech Republic, Denmark, France, Germany, Italy, Luxembourg, the Netherlands, New Zealand, Norway, Sweden, Switzerland, the United Kingdom, and the United States. The primary analysis included 2800 participants (98.2%), of whom 1403 were assigned to the hypothermia group and 1397 were assigned to the normothermia group (Table 1). Patient characteristics and delivered medical care were similar at baseline (Table 1). Temperature curves are displayed in Figure SIA and SIB.

---

**RISK OF BIAS**

Both the TTM and TTM2 trials were externally assessed to be at low risk of bias (Table S2).

**PRIMARY OUTCOME**

In total, data on mortality were missing for 11 of 2800 participants (0.4%) (Table S3). Death occurred for 691 of 1398 participants (49.4%) in the hypothermia group and 666 of 1391 participants (47.9%) in the normothermia group (relative risk with hypothermia, 1.03; 95% CI, 0.96 to 1.11; P=0.41) (Fig. 1). The Bayes factor demonstrated that this result was over 25,000 times more likely under the assumption of a hypothesis that hypothermia reduces the relative risk of death by 13.6% (see Fig. S2 for a graphical presentation of the Bayes factor as a function of relative risk reduction of 0% to 20%). Trial sequential analysis showed that we could reject the hypothesis that hypothermia reduces or increases the relative risk of death by 10% (Fig. S3A). None of the preplanned tests of interaction for subgroups, including initial shockable compared with nonshockable cardiac rhythm, showed evidence of a difference (Fig. 1). In a post hoc analysis of subgroups, patients with bystander resuscitation had higher mortality with hypothermia (Fig. 1).

**SECONDARY OUTCOMES**

Data on functional outcome were missing for 120 of 2800 participants (4.3%) (Table S3). At 6 months, 733 of 1350 participants (54.3%) in the hypothermia group and 718 of 1330 participants (54.0%) in the normothermia group had a poor functional outcome (relative risk with hypothermia, 1.01; 95% CI, 0.94 to 1.08; P=0.88) (Fig. 2). The Bayes factor demonstrated that this result was over 9000 times more likely under the assumption of the null hypothesis than under the assumption of a hypothesis that hypothermia reduces the relative risk of a poor functional outcome by 13.6% (Fig. S2). Trial sequential analysis showed that we could reject the hypothesis that hypothermia reduces or increases the relative risk of a poor functional outcome by 8% (Fig. S3B). None of the predefined tests of interaction for subgroups, including initial shockable compared with nonshockable cardiac rhythm, showed evidence of a difference (Fig. 2). In a post hoc analysis of subgroups, patients without bystander resuscitation had better functional outcome with hypothermia (Fig. 2) while there was no differentiated effect in MIRACLE2 severity classes. The remaining post hoc subgroup analyses showed no evidence of a difference.
There were no intervention-related significant differences in the occurrence of the prespecified adverse events of pneumonia (relative risk with hypothermia, 1.06; 95% CI, 0.97 to 1.15; P = 0.19), sepsis (relative risk with hypothermia, 1.14; 95% CI, 0.91 to 1.42; P = 0.25), or severe bleeding (relative risk with hypothermia, 0.95; 95% CI, 0.69 to 1.28; P = 0.74) (Table S3). Trial sequential analyses showed that we could reject that hypothermia reduces or increases the relative risk of pneumonia by 13%, sepsis by 28%, and severe bleeding by 32% compared with normothermia. Forest plots and trial sequential analyses are reported in Figures S4 through S9.

### Table 1. Patient Characteristics.

<table>
<thead>
<tr>
<th>Characteristic</th>
<th>Normothermia (n=1397)</th>
<th>Hypothermia (n=1403)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age — Mean (SD) — yr</td>
<td>63.4 (13.5)</td>
<td>64.4 (12.8)</td>
</tr>
<tr>
<td>Male sex — No. (%)</td>
<td>1103 (79.0)</td>
<td>1135 (80.9)</td>
</tr>
<tr>
<td>Medical history (known/previous) — No. (%)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Heart failure</td>
<td>122 (8.7)</td>
<td>122 (8.7)</td>
</tr>
<tr>
<td>Unknown</td>
<td>52 (3.7)</td>
<td>41 (2.9)</td>
</tr>
<tr>
<td>Acute myocardial infarction</td>
<td>240 (17.2)</td>
<td>246 (17.5)</td>
</tr>
<tr>
<td>Unknown</td>
<td>52 (3.7)</td>
<td>40 (2.9)</td>
</tr>
<tr>
<td>Coronary-artery bypass grafting</td>
<td>118 (8.4)</td>
<td>120 (8.6)</td>
</tr>
<tr>
<td>Unknown</td>
<td>54 (3.9)</td>
<td>40 (2.9)</td>
</tr>
<tr>
<td>PCI</td>
<td>190 (13.6)</td>
<td>188 (13.4)</td>
</tr>
<tr>
<td>Unknown</td>
<td>54 (3.9)</td>
<td>40 (2.9)</td>
</tr>
<tr>
<td>Hypertension</td>
<td>479 (34.3)</td>
<td>538 (38.3)</td>
</tr>
<tr>
<td>Unknown</td>
<td>54 (3.9)</td>
<td>40 (2.9)</td>
</tr>
<tr>
<td>Cardiac arrest — No. (%)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>First monitored rhythm</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ventricular fibrillation</td>
<td>941 (67.4)</td>
<td>925 (65.9)</td>
</tr>
<tr>
<td>Nonperfusing VT</td>
<td>41 (2.9)</td>
<td>43 (3.1)</td>
</tr>
<tr>
<td>Asystole</td>
<td>154 (11.0)</td>
<td>183 (13.0)</td>
</tr>
<tr>
<td>PEA</td>
<td>141 (10.1)</td>
<td>154 (11.0)</td>
</tr>
<tr>
<td>Unknown, no shock administered</td>
<td>24 (1.7)</td>
<td>20 (1.4)</td>
</tr>
<tr>
<td>Unknown, shock administered</td>
<td>50 (3.6)</td>
<td>45 (3.2)</td>
</tr>
<tr>
<td>ROSC after bystander defibrillation</td>
<td>45 (3.2)</td>
<td>33 (2.4)</td>
</tr>
<tr>
<td>Unknown</td>
<td>1 (0.1)</td>
<td>0 (0.0)</td>
</tr>
<tr>
<td>Time to ALS — median (IQR) — min</td>
<td>10 (6, 14)</td>
<td>10 (6, 15)</td>
</tr>
<tr>
<td>Time to ROSC — median (IQR) — min</td>
<td>25 (17, 40)</td>
<td>25 (17, 40)</td>
</tr>
<tr>
<td>Clinical characteristics on admission</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Initial temperature — mean (SD) — °C</td>
<td>35.4 (1.1)</td>
<td>35.3 (1.2)</td>
</tr>
<tr>
<td>Corneal reflex present — No. (%)</td>
<td>451 (32.3)</td>
<td>431 (30.7)</td>
</tr>
<tr>
<td>Unknown</td>
<td>470 (33.6)</td>
<td>486 (34.6)</td>
</tr>
<tr>
<td>Pupillary reflex present — No. (%)</td>
<td>890 (63.7)</td>
<td>878 (62.6)</td>
</tr>
<tr>
<td>Unknown</td>
<td>165 (11.8)</td>
<td>183 (13.0)</td>
</tr>
<tr>
<td>pH — mean (SD)</td>
<td>7.19 (0.15)</td>
<td>7.19 (0.16)</td>
</tr>
<tr>
<td>Lactate — mean (SD) — mmol/liter</td>
<td>6.12 (4.28)</td>
<td>6.17 (4.46)</td>
</tr>
<tr>
<td>Circulatory shock — No. (%)</td>
<td>342 (24.5)</td>
<td>331 (23.6)</td>
</tr>
<tr>
<td>Unknown</td>
<td>1 (0.1)</td>
<td>1 (0.1)</td>
</tr>
<tr>
<td>ST-segment elevation myocardial infarction — No. (%)</td>
<td>564 (40.4)</td>
<td>569 (40.6)</td>
</tr>
<tr>
<td>Unknown</td>
<td>14 (1.0)</td>
<td>19 (1.4)</td>
</tr>
</tbody>
</table>

* ALS denotes advanced life support; IQR, interquartile range; min, minutes; PCI, percutaneous coronary intervention; PEA, pulseless electrical activity; ROSC, return of spontaneous circulation; VT, ventricular tachycardia.
Figure 1. Fixed-Effects Meta-Analysis of Overall All-Cause Mortality at 6 months and Stratified by Subgroup.

All-cause mortality at 6 months, both overall and stratified by subgroup. For all-cause mortality, a fixed-effects meta-analysis was performed. Fixed-effects meta-analysis showed no evidence of a difference between hypothermia and normothermia on the risk of death (risk ratio, 1.03; 95% CI, 0.96 to 1.11; P = 0.41). ALS denotes advanced life support; CI, confidence interval; CPR, cardiopulmonary resuscitation; ROSC, return of spontaneous circulation; TTM1, Targeted Temperature Management at 33°C versus 36°C after Cardiac Arrest; and TTM2, Hypothermia versus Normothermia after Out-of-Hospital Cardiac Arrest.
Figure 2. Random-Effects Meta-Analysis of Overall Poor Functional Outcome at 6 months and Stratified by Subgroup.

Poor functional outcome at 6 months, both overall and stratified by subgroup. For poor functional outcome, a random-effects meta-analysis was performed. A poor functional outcome was defined as a modified Rankin scale score of 4 to 6. Random-effects meta-analysis showed no evidence of a difference between hypothermia and normothermia on the risk of a poor functional outcome (risk ratio, 1.01; 95% CI, 0.94 to 1.08; P = 0.88). MIRACLE2 risk groups indicate severity and worse prognosis at admission, and the groups are defined as low risk for a score of 0 to 2, medium for 3 to 5, and high for 6 to 10.15 ALS denotes advanced life support; CI, confidence interval; CPR, cardiopulmonary resuscitation; ROSC, return of spontaneous circulation; TTM1, Targeted Temperature Management at 33°C versus 36°C after Cardiac Arrest; and TTM2, Hypothermia versus Normothermia after Out-of-Hospital Cardiac Arrest.
EXPLORATORY OUTCOMES

Time to death was similar in both the hypothermia and normothermia groups (hazard ratio with hypothermia, 1.08; 95% CI, 0.97 to 1.20; P = 0.15), and the complementary log-rank test also showed no difference (P = 0.16) (Fig. 3).

Modified Rankin scale scores (ordinal data) showed no difference between the hypothermia and normothermia groups (P = 0.44) (Fig. 4).

For a presentation of functional outcome according to MIRACLE2 scores as observed for the cohort as a whole and dispersion of the study population over the risk scores, see Figure 5A. We found no evidence of interaction (P = 0.42) when stratifying patients based on low, intermediate, or high MIRACLE2 risk groups (Fig. 5B). This was performed as a post hoc analysis.

Discussion

In this individual patient data meta-analysis of the TTM and TTM2 trials, we found that there was no benefit of hypothermia at 33°C compared with normothermia on survival or functional outcome at 6 months among adult patients surviving out-of-hospital cardiac arrest attributed to a cardiac etiology. We found no signs of heterogeneity between the two trials. These findings are confirmatory of the results of the individual trials.6,8 Furthermore, there was no benefit of hypothermia on mortality or functional outcome in any of the prespecified subgroups representing certain conditions of the cardiac arrest or patient characteristics, including for nonshockable compared with shockable initial rhythm of the cardiac arrest. Finally, post hoc analysis suggested higher mortality in patients with bystander resuscitation treated...
with hypothermia, whereas patients without bystander resuscitation had better functional outcome with hypothermia. We did not find evidence of interaction when stratifying patients based on low, intermediate, or high MIRACLE2 risk groups, suggesting that the treatment effect of hypothermia is not dependent on the overall severity of the insult.

The type of temperature control to induce and maintain hypothermia that has been investigated in clinical trials and utilized clinically the last two decades does not, according to our results as well as recent systematic reviews with traditional meta-analysis, appear to provide the intended benefit. Of note, our present results relate to the potential effect of two different temperature control strategies — namely, hypothermia at 33°C and targeted normothermia (36° to 37.8°C) — delivered during a 36- to 40-hour period, and we thus did not investigate the potential effects of duration, speed of achieving hypothermia, or modality of temperature control (e.g., surface cooling, intravascular cooling, or other method of achieving cooling). If future trials in hypothermia after cardiac arrest are to be conducted, the design of such should be informed by updated experimental data, as systematic review with meta-analyses of animal studies points to quality issues and knowledge gaps in the existing evidence.

Figure 5. Assessment of Severity by Applying the MIRACLE2 Score.

Panel A shows the observed functional outcome as a function of MIRACLE2 score on an ordinal scale and indicates the number of patients assigned to each score (not stratified by treatment group). Bars denote the percentage of poor outcomes, whereas dots indicate the total number of patients. Panel B shows the observed functional outcome stratified by low, medium, or high MIRACLE2 risk group and assignment to the hypothermia or normothermia group. This was performed as a post hoc analysis. MIRACLE2 is a validated score that can be applied at hospital admission for assessing the risk of a poor neurologic outcome. The score ranges from 1 to 10 (a higher score indicates worse prognosis) and includes the following: Missed (unwitnessed arrest), Initial rhythm (not shockable), Reactive pupils (no pupillary reflex), Age (older than 60 or older than 80 years of age), Changing rhythms (any two of ventricular fibrillation, pulseless electrical activity, or asystole), Low pH (pH<7.2) and Epinephrine given (adrenaline given). MIRACLE2 risk groups indicate severity and worse prognosis at admission and the groups are defined as low risk for a score of 0 to 2, medium for 3 to 5, and high for 6 to 10. Further for a further description, please see the analysis of severity discussion in the Supplementary Appendix.

Trial sequential analyses, a method of estimating the number of participants needed to detect or reject a certain effect size, were performed to determine at what level we could rule out an effect of hypothermia compared with normothermia. This analysis revealed that we can reject the hypotheses of a relative risk benefit of hypothermia as subtle as 10% for mortality and 8% for poor functional outcome. Smaller yet clinically relevant effect sizes are still plausible. Bayes factor calculations for both all-cause mortality and poor functional outcome show that it would be far more likely to find no benefit of targeted hypothermia than benefit. Furthermore, the potential costs accompanying treatment with hypothermia, as well as the substantial number of participants needed to investigate smaller intervention effects, should also be taken into account when considering further trials.

The HYPERION trial is the only other major trial besides the TTM and TTM2 trials on temperature control after out-of-hospital cardiac arrest since 2002. Our findings contrast the main finding of the HYPERION trial of an
apparent benefit of hypothermia on functional outcome. This difference might reflect the statistical fragility of the smaller HYPERION trial but may also result from differences in the enrolled patients and implementation of temperature control. The present individual patient data meta-analysis included both patients with initial shockable and nonshockable cardiac rhythms, while the HYPERION trial only included patients with nonshockable rhythms. However, our results do not indicate a differentiated treatment response to targeted hypothermia per initial cardiac rhythm, and the test of interaction in the present study is based on a larger sample size and more events than the HYPERION trial. Furthermore, the HYPERION trial included patients with cardiac arrest from all etiologies and a mix of patients with in- and out-of-hospital cardiac arrest, and the suggested effect was mainly in the in-hospital group. The TTM and TTM2 trials excluded patients with noncardiac causes of the cardiac arrest and included only patients with out-of-hospital cardiac arrest.

Based on observational studies and from theoretical extrapolation, it has been put forward that specific phenotypes of cardiac arrests might benefit from hypothermia. Surrogate markers of the severity of hypoxic-ischemic encephalopathy such as duration of the cardiac arrest and bystander cardiopulmonary resuscitation have been suggested to modify the effect of hypothermia. In addition, based on the overall magnitude of the cardiac arrest ischemia, defined by risk classes, both patients with high and medium risk of a poor outcome have been suggested to benefit from hypothermia at 33°C. Our subgroup analyses are based on randomized data and have more statistical power than any previous material to date. In the predefined subgroups based on the design variables in the TTM and TTM2 trials, there were no signals of a differentiated effect between hypothermia and normothermia. However, in a post hoc analysis, we found a signal of potential harm with hypothermia in patients who had received bystander cardiopulmonary resuscitation, as hypothermic temperature control was associated with increased mortality compared with normothermic temperature control. We found a signal of benefit with hypothermia in patients who had not received bystander cardiopulmonary resuscitation, as hypothermic temperature control was associated with a higher incidence of a good functional outcome compared with normothermic temperature control. These post hoc subgroup analyses should be interpreted with great caution, owing to problems with multiplicity, no clear pattern in relation to other subgroups, and lack of supporting data tying a treatment effect of hypothermia to the severity of the ischemic insult, as our analysis using the validated MIRACLE2 severity classification did not indicate a difference in outcome. Two thirds of patients in the combined TTM and TTM2 population were defined as having a medium or high risk, suggesting a severely injured population included in the trials.

The main limitation with the TTM trials and with their interpretation in regard to effects of temperature control and fever prevention is that the control groups were designed with the prevailing notion that hypothermia and fever management is of benefit, even if that notion was based on low-certainty evidence and observational data. Therefore, the 36°C arm of the TTM trial was the highest possible target temperature within the range of normothermia that was accepted by the research and clinical community in 2010. In 2017, with the neutral results of the TTM trial present, it was acceptable to stretch the highest possible target to strict normothermia to prevent fever using a conservative definition of 37.8°C or higher. Both control arms thus represent active intervention (100% had a temperature device in the control group of the TTM trial and 46% in the TTM2 trial). Hence, the interpretation of the TTM trials and this current independent data meta-analysis is complicated by the fact that there was no control group in which temperature control using a temperature device was not allowed. It is therefore uncertain whether the neutral effect of the trials and this meta-analysis is attributable to both temperature interventions being beneficial, ineffective, or even harmful. A large trial of fever management with temperature devices to target normothermia compared with no use of temperature devices is necessary to answer this question.

The results of this individual patient data meta-analysis are informative but do not directly relate to the treatment of patients with noncardiac causes of cardiac arrest, in-hospital cardiac arrests, or for different strategies of achieving hypothermic temperature control. There is, however, at least one randomized trial registered at ClinicalTrials.gov for the in-hospital cardiac arrest group, which is reported as completed but still not published (HCAInhospital, NCT00457431), and there is an ongoing large trial of different durations of hypothermia delivered within 4 hours after out-of-hospital cardiac arrest (ICECAP, NCT04217551). In conclusion, this individual patient data analysis found no benefit of hypothermia compared with normothermia.
with respect to mortality for patients with out-of-hospital cardiac arrest.

Disclosures
Supported by grants 2016-00428 and 2017-02627 from Vetenskapsrådet. Author disclosures and other supplementary materials are available at evidence.nejm.org.

We thank Lawrence Mbuagbaw, M.D., M.P.H., Ph.D., of McMaster University in Hamilton, Ontario, Canada, for the risk of bias assessment.

Author Affiliations
1 Anesthesiology and Intensive Care, Department of Clinical Sciences, Helsingborg Hospital Lund, Lund University, Lund, Sweden
2 Department of Cardiology, The Heart Centre, Copenhagen University Hospital Rigshospitalet, Copenhagen
3 Cardiology, Department of Clinical Sciences, Skåne University Hospital Lund, Lund University, Lund, Sweden
4 Neurology, Department of Clinical Sciences, Skåne University Hospital Lund, Lund University, Lund, Sweden
5 Clinical Studies Sweden- Forum South, Skåne University Hospital, Lund, Sweden
6 Adult Critical Care, University Hospital of Wales, Cardiff, United Kingdom
7 Cardiovascular Medicine, Second Department of Medicine, General University Hospital, First Faculty of Medicine, Charles University, Prague, Czech Republic
8 Division of Emergencies and Critical Care, Department of Anesthesiology, Oslo University Hospital, Rikshospitalet, Oslo
9 Department of Surgical Sciences and Integrated Diagnostics, University of Genoa, Genoa, Italy
10 Anesthesiology and Critical Care, San Martino Policlinico Hospital, Scientific Institute for Research, Hospitalization and Healthcare for Oncology and Neurosciences, University of Genoa, Genoa, Italy
11 Intensive Care Department, Kantonspital St. Gallen, St. Gallen, Switzerland
12 Department of Anesthesiology and Intensive Care Medicine, Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden
13 Intensive Care Unit, Medical Research Institute of New Zealand, Wellington Hospital, Wellington, New Zealand
14 Division of Critical Care and Trauma, George Institute for Global Health, Sydney
15 Department of Intensive Care, Liverpool Hospital, Sydney
16 Cochin University Hospital, Descartes University of Paris, Paris
17 Department of Emergency Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania
18 Australian and New Zealand Intensive Care Research Centre, Monash University, Melbourne, Australia
19 Department of Intensive Care Medicine, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland
20 Division of Intensive and Emergency Medicine, Department of Internal Medicine, Medical University Innsbruck, Innsbruck, Austria
21 Essex Cardiothoracic Centre, Basildon, United Kingdom
22 Anglia Ruskin School of Medicine, Chelmsford, Essex, United Kingdom
23 Department of Clinical Medicine, Research Center for Emergency Medicine, Aarhus University Hospital, Aarhus University, Aarhus, Denmark
24 Klinik und Hochschulambulanz für Neurologie, Charité-Universitätsmedizin, Berlin
25 Anesthesiology and Intensive Care, Department of Clinical Sciences, Skåne University Hospital Lund, Lund University, Lund, Sweden
26 University College Dublin Clinical Research Centre, St. Vincent’s University Hospital, Dublin
27 School of Public Health and Preventive Medicine, Australian and New Zealand Intensive Care Research Centre, Monash University, Melbourne, Australia
28 Department of Clinical Science and Education, Center for Resuscitation Science, Karolinska Institutet, Södersjukhuset, Stockholm
29 Adult Intensive Care Medicine Service, Neuroscience Critical Care Research Group, Vaud University Hospital Center, University of Lausanne, Lausanne, Switzerland
30 Department of Nephrology and Medical Intensive Care, Charity-Universitätsmedizin Berlin, Berlin
31 Department of Intensive Care, Erasme University Hospital, Université Libre de Bruxelles, Brussels
32 Department of Intensive Care, Bristol Royal Infirmary, Bristol, United Kingdom
33 Department of Intensive Care, Academic Medical Center, Amsterdam
34 Department of Intensive Care, Medical Center Leeuwarden, Leeuwarden, The Netherlands
35 Intensive Care Unit, Santa Maria degli Angeli, Pordenone, Italy
36 Department of Intensive Care Medicine, Centre Hospitalier de Luxembourg, Luxembourg, Luxembourg
37 Department of Life Sciences and Medicine, Faculty of Science, Technology and Medicine, University of Luxembourg, Esch-sur-Alzette, Luxembourg
38 Anesthesia and Intensive Care, Department of Clinical Sciences, Skåne University Hospital Malmo, Lund University, Lund, Sweden
39 Copenhagen Trial Unit, Center for Clinical Intervention Research, Copenhagen University Hospital, Copenhagen
40 Department of Regional Health Research, Faculty of Health Sciences, University of Southern Denmark, Odense, Denmark

References


